



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁵ : A61K 37/547, 37/02, 35/16</p>	A1	<p>(11) International Publication Number: WO 95/01804 (43) International Publication Date: 19 January 1995 (19.01.95)</p>
<p>(21) International Application Number: PCT/SE94/00297 (22) International Filing Date: 31 March 1994 (31.03.94) (30) Priority Data: 9302308-3 5 July 1993 (05.07.93) SE (71) Applicant (for all designated States except US): PHARMACIA AB [SE/SE]; Patent Dept., S-112 87 Stockholm (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): SPIRA, Jack [SE/SE]; Tottvägen 6, S-171 35 Stockholm (SE). WIDLUND, Lars [SE/SE]; Stadingeplan 1, S-163 63 Spånga (SE). ÖSTERBERG, Thomas [SE/SE]; Folkungagatan 88 B, S-116 22 Stockholm (SE). (74) Agents: TANNERFELDT, Agneta et al.; Pharmacia AB, Patent Dept., S-112 87 Stockholm (SE).</p>	<p>(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: A COAGULATION FACTOR VIII FORMULATION</p>		
<p>(57) Abstract</p>		
<p>The present invention relates to a pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising recombinant coagulation factor VIII and use thereof for manufacture of a medicament for treating haemophilia. The formulation comprises a highly purified recombinant coagulation factor VIII in a concentration of at least 1000 IU/ml, which gives surprisingly high levels of active factor VIII in the blood stream after subcutaneous, intramuscular or intradermal administration. The formulation is intended for treatment of haemophilia by subcutaneous, intramuscular or intradermal administration. The recombinant factor VIII is preferably a deletion derivative thereof, which can be used for the manufacture of a medicament for subcutaneous administration.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

A coagulation factor VIII formulation.

The present invention relates to a pharmaceutical formulation for
5 subcutaneous, intramuscular or intradermal administration comprising recombinant coagulation factor VIII and use thereof for manufacture of a medicament for treating haemophilia. The formulation comprises a highly purified recombinant coagulation
10 factor VIII in a concentration of at least 1000 IU/ml, which gives surprisingly high levels of active factor VIII in the blood stream after subcutaneous, intramuscular or intradermal administration. The formulation is intended for treatment of haemophilia by subcutaneous, intramuscular or intradermal administration. The recombinant factor VIII is preferably a deletion derivative thereof,
15 which can be used for the manufacture of a medicament for subcutaneous administration.

Background of the invention

20 Haemophilia is an inherited disease which has been known for centuries but it is only within the last three decades that it has been possible to differentiate between the various forms; haemophilia A, haemophilia B and haemophilia C. Haemophilia A is the most frequent form. It affects only males with an incidence
25 of one or two individuals per 10 000 live-born males. The disease is caused by strongly decreased level or absence of biologically active coagulation factor VIII (antihæmophilic factor), which is a protein normally present in plasma. The clinical manifestation of haemophilia A is a strong bleeding tendency and before
30 treatment with factor VIII concentrates was introduced, the mean age of those patients was less than 20 years. Concentrates of factor VIII obtained from plasma have been available for about three decades. This has improved the situation for treatment of haemophilia patients considerably and given them
35 possibility to live a normal life.

Therapeutic factor VIII concentrates have until now been prepa-

red by fractionation of plasma. However, there are now methods available for production of factor VIII in cell culture using recombinant DNA techniques as reported in e.g. J Gitschier et al. Nature 312, p. 330-37, 1984 and EP-A-160 457.

5

Factor VIII concentrates derived from human plasma contain several fragmented fully active factor VIII forms (Andersson et al, Proc. Natl. Acad. Sci. USA, Vol 83, p. 2979-83, May 1986). The smallest active form has a molecular mass of 170 kDa and consists of two chains of 90 kDa and 80 kDa held together by a metal ion bridge. Reference is here made to EP-A-197 901.

10 Kabi Pharmacia has developed a recombinant factor VIII product which corresponds to the 170 kDa plasma factor VIII form in therapeutic factor VIII concentrates. The truncated recombinant factor VIII molecule is termed r-VIII SQ and is produced by
15 Chinese Hamster Ovary (CHO) cells in a cell culture process in serum-free medium.

The structure and biochemistry of recombinant factor VIII products in general have been described by Kaufman in Tibtech, Vol 9,
20 1991 and Hematology, 63, p. 155-65, 1991. The structure and biochemistry of r-VIII SQ have been described in WO-A-91/09122.

Large proteins are normally given intravenously so the medicament is
25 directly available in the blood stream. It would however be advantageous if a medicament could be given subcutaneously, intramuscularly or intradermally as these administration forms are much easier to handle for the patient. Especially if the medicament must be taken regularly during the whole life and treatment is to start early, already
30 when the patient is a child.

However, a medicament with a very large and labile molecule, such as coagulations factor VIII of 170 to 300 kDa, have normally a very low bioavailability if given subcutaneously, intramuscularly or intradermally, since the uptake is not enough and degradation is severe. To
35 our knowledge, the only coagulation factor protein which has been administered by subcutaneous injection is factor IX (90 kDa).

All presently available factor VIII preparations on the market are made as a formulation for intravenous administration and are stabilised with human serum albumin.

5 Description of the invention

To our great surprise we have found that factor VIII, which is a very sensitive protein, can be given subcutaneously and, in contrast to all earlier experience we obtain an acceptable absorption and a high level
10 of active factor VIII protein in the blood.

We have thus developed a formulation which makes it possible to administer factor VIII subcutaneously, intramuscularly or intradermally and which gives a great advantage for all patients in need of
15 factor VIII.

Recombinant factor VIII SQ is indicated for treatment of classical haemophilia.

The half-life for r-VIII SQ is approximately 12 hours for humans
20 when injected intravenously.

For prophylactic treatment 15-25 IU/kg bodyweight is given of factor VIII three times a week. An intravenous injection is normally 5-10 ml.

An injection given subcutaneously is between 0.05 to 1 ml and the
25 concentration of factor VIII must therefore be very high in such a formulation.

This is possible to obtain e.g. with our highly purified recombinant factor VIII.

30 The inventive idea is thus a combination of the finding that factor VIII can be absorbed into the blood-stream when given as a subcutaneous, intramuscular or intradermal pharmaceutical formulation and that it is possible to produce a formulation comprising the required high concentration of factor VIII for this purpose.

35

The present invention relates to a pharmaceutical formulation

for subcutaneous, intramuscular or intradermal administration comprising highly purified recombinant coagulation factor VIII in a concentration of at least 1000 IU/ml, which formulation gives a therapeutic level of factor VIII activity in the blood after administration.

The composition is preferably given subcutaneously. The factor VIII activity in the formulation is at least 1000 IU/ml, preferably more than 1500 IU/ml and most preferably from 5000 to 100 000 IU/ml.

The volume given is suitably 0.1 to 2 ml, preferably 0.25 to 1.5 ml, and more preferably 0.5 to 1 ml. The volume can also be 0.1 to 1 ml.

Factor VIII is recombinant and it can be either in its full-length form or preferably a deletion derivative thereof. More preferably the deletion derivative is recombinant factor VIII SQ (r-VIII SQ). By deletion derivative is here meant coagulation factor VIII, in which the whole or part of the B-domain is missing. Additionally, the r-VIII SQ molecule can be chemically modified, e.g. by pegylation, covalently linked carbohydrates or polypeptides, in order to improve the stability of the molecule in vivo.

Our used factor VIII is highly purified, i.e. has a specific activity of more than 5000 IU/mg protein, even more than 12 000 IU/mg and is preferably stabilized without the addition of albumin.

The formulation can also comprise sodium or potassium chloride, preferably in an amount of more than 0.1 M.

Calcium (or other divalent metal ions) is necessary for the maintenance of the association of factor VIII heavy and light chain. It is here added as calcium chloride (CaCl₂) but other salts such as calcium gluconate, calcium glubionate or calcium gluceptate can also be used. The composition comprises preferably calcium chloride or calcium gluconate in an amount of more than 0.5 mM.

An amino acid is preferably used to buffer the system and it also

protects the protein in the amorphous phase if the formulation is freeze-dried. A suitable buffer could be L-histidine, lysine and/or arginine. L-Histidine has primarily been chosen because of the good buffer capacity of L-histidine around pH 7.

5

The formulation could comprise

- i) at least 1500 IU/ml of a deletion derivative of recombinant factor VIII
- 10 ii) at least 0.01 mg/ml of a polyoxyethylene sorbitan fatty acid ester
- iii) sodium chloride, preferably in an amount of more than 0.1 M.
- iv) calcium salt, such as calcium chloride or calcium gluconate, preferably in an amount of more than 0.5 mM.
- 15 v) an amino acid such as L-histidine in an amount of more than 1 mM.

A non-ionic surfactant can also be present in the formulation and is then preferably chosen from block co-polymers, such as a polyoxamer or polyoxyethylene sorbitan fatty acid ester, such as polyoxyethylene-(20)-sorbitan monolaurate or polyoxyethylene-(20)-sorbitan monooleate. The non-ionic surfactant, if used, should preferably be present in an amount above the critical micelle concentration (CMC). See Wan and Lee, Journal of Pharm Sci, 63, p. 136, 1974.

25 The polyoxyethylene sorbitan fatty acid ester is preferably used in an amount of at least 0.01 mg/ml.

To this formulation mono- or disaccharides or sugar alcohols, preferably sucrose, could be added. Also antioxidants such as glutathione, acetylcystein, tocopherol, methionin, EDTA, citric acid, 30 butyl hydroxy toluene and/or butyl hydroxy anisole could be added. Furthermore, preservatives such as benzyl alcohol, phenol, sorbic acid, parabens and chlorocresol could be added.

35 The formulation comprises preferably L-histidine and sucrose. The ratio of sodium chloride to L-histidine and sucrose in the

composition for freeze-drying is suitably more than 1:1 (w:w), preferably more than 2:1 (w:w).

5 The formulation could be in a dried form, preferably freeze-dried. The dried product is reconstituted with sterile water for injection or a pharmaceutically acceptable buffer solution, or mixed or reconstituted with an aqueous solution containing absorption enhancers or protease inhibitors before administration.

10 The claimed formulation can also be a stable aqueous solution ready for administration. It can also be a dispersion, e.g. a suspension, a liposomal formulation or an emulsion.

15 The formulation could be stored in an oxygen-reduced environment as disclosed in the copending patent application PCT/SE94/00265.

20 Absorption enhancers or protease inhibitors could be added. Examples of suitable absorption enhancers are phospholipids, fatty acids, bile salts, salicylates and EDTA. Examples of suitable protease inhibitors are aprotinin and EDTA.

25 The claimed formulation can be prepared by mixing factor VIII with a non-ionic surfactant in an aqueous solution, preferably together with an amino acid such as L-histidine, sodium salt, sucrose and a calcium salt or by eluting factor VIII from the last purification step with a buffer containing a non-ionic surfactant in an aqueous solution, preferably together with sodium salt, sucrose, calcium salt and an amino acid such as L-histidine.

30 The invention also relates to the use of the claimed formulation for the manufacture of a medicament for subcutaneous, intramuscular or intradermal administration for treating haemophilia, preferably for the use of a deletion derivative of recombinant
35 factor VIII for the manufacture of a medicament for subcutaneous administration. The medicament can be in a stable aqueous solution or dispersion, or freeze-dried. It also relates to a method

for treatment of haemophilia by subcutaneous, intramuscular or intradermal administration of the claimed formulation.

5 The data presented in the examples indicate that r-VIII SQ can be injected subcutaneously and recovered in an active form intravenously in vivo. This is a very surprising finding, as no such formulation have been known earlier.

10 The protection is not limited to a composition under these examples.

EXPERIMENTAL

Material and methods

15 The production of recombinant factor VIII SQ (r-VIII SQ) was essentially performed as described in patent WO-A-91/09122, example 1-3. A DHFR deficient CHO celline (DG44N.Y.) was electroporated with an expression vector containing the r-VIII SQ gene and an expression vector containing the dihydrofolate-reductase gene. Following selection on selective media surviving colonies were amplified through growth in stepwise increasing amounts of methotrexate. Supernatant from the resulting colonies were individually screened for factor VIII activity. A production clone was chosen and this was subsequently adapted to serum free suspension growth in a defined medium and finally a large scale fermentation process was developed. Supernatant is collected after certain time periods and further purified as described below.

25
30 The clarified conditioned medium was pH adjusted and applied to a S-Sepharose FF column. After washing, factor VIII was eluted with a salt buffer containing 5 mM CaCl₂.

35 Immunoabsorption was carried out on an immunoaffinity resin where the ligand was a monoclonal antibody (8A4) directed towards the heavy chain of factor VIII. Before loading to the column the S-eluate was treated with 0.3 % TNBP and 1 % Octoxynol 9.

The column was equilibrated, washed and factor VIII was eluted with a buffer containing 0.05 M CaCl₂ and 50 % ethylene glycol.

5 The mAb-eluate was loaded on a Q-Sepharose FF column, equilibrated with the elution buffer in the immunoaffinity step. After washing, factor VIII was eluted with 0.05 M L-Histidine, 0.6 M sodium chloride, 4 mM calcium chloride and pH 6.8.

10 The Q-eluate was applied to a gel filtration column (Superdex 200 p.g.). Equilibration and elution was carried out with a buffer containing L-histidine, sodium chloride and calcium chloride.

The protein peak was collected and the solution was formulated before freeze-drying.

15 This material of r-VIII SQ was received from the final purification step. The factor VIII activity and the concentration of the inactive components were adjusted by diluting with an appropriate buffer containing polyethylene glycol (PEG). The solution was then sterile filtered (0.22 μ m), dispensed and freeze-dried.

20

EXAMPLE 1

Recombinant factor VIII was prepared according to the method described under Experimental.

25 The freeze-dried composition containing r-VIII SQ was the following per vial, which was reconstituted in 4 ml sterile water for injection:

Composition per vial:		
	L-Histidine, mg	31.0
30	Sodium chloride, mg	70.1
	Calcium chloride · (2 H ₂ O), mg	2.35
	Polyethylene glycol (PEG 4000), mg	4.0
	Polyoxyethylene-(20)-sorbitan monooleate (Tween 80®), mg	1
35	VIII:C charged, IU/vial	4400
	VIII:C in reconstituted solution, IU/ml	1060

Male albino mice weighing about 30 g and of strain NMRI, SPF, were injected subcutaneously in the neck with the reconstituted r-VIII SQ solution.

The volume injected at the dose level of 10 000 IU/kg was 9.4 ml/kg and at the higher dose level 50 000 IU/kg, 5 times larger, 47 ml/kg. In the placebo treatment saline was used, 9.4 ml/kg. 3-5 minutes before the blood sampling the mice were anaesthetized intra peritoneally with Mebumal® (pentobarbital) vet. 60 mg/ml. The volume injected was 9.4 ml/kg i.e. about 0.3 ml/- mouse. Under the anaesthesia 0.45 ml blood was collected from the vena cava in plastic syringes containing 0.05 ml 0.13 M sodium citrate. Plasma was then prepared from the collected blood by centrifugation (8800 g for 7 minutes) and kept frozen in plastic Cryoflex tubes at -70°C until the time of determination of factor VIII activity.

Results:

TABLE 1

VIII:C in plasma from mice receiving r-VIII SQ 10 000 IU/kg body weight subcutaneously.

	Time after administration (hours)	VIII:C (IU / ml) X ± Sd	n number of observations
25	0	0.82 ± 0.43	12
	0.33	1.23 ± 0.41	3
	1.0	1.38 ± 0.56	4
30	1.5	1.83 ± 0.60	12
	2.0	1.43 ± 0.91	8
	4.0	1.34 ± 0.72	6
	6.0	1.27 ± 0.42	4
	8.0	1.55 ± 0.80	4
35	16.0	0.62 ± 0.28	4
	20.0	0.58 ± 0.12	3
	24.0	0.76 ± 0.53	4

TABLE 2.

Dose - Response in mice receiving r-VIII SQ subcutaneously.

Dose: Dose r-VIII SQ administered (IU/kg).

5 Response: VIII:C in plasma (IU/ml) 1.5 hours after subcutaneous administration.

	Dose (IU/kg)	Response (IU/ml)	Response (IU/ml) (baseline adjusted)	n number of obs.
10	Blank (baseline)	0.82 ± 0.43	-	12
15	Saline	1.21 ± 0.34	0.39	4
	10 000	1.83 ± 0.60	1.01	12
	50 000	2.47 ± 0.60	1.65	6

Results

20

1. The change of VIII:C in plasma with time after a subcutaneous dose of r-VIII SQ, 10 000 IU/kg, shows the typical pattern for a drug being absorbed from a subcutaneous depot (see Table 1). The maximum VIII:C level in plasma is seen at about 1.5 hours after administration (see Table 1).

25

2. The absorption of r-VIII SQ from a subcutaneous depot is further verified by the increase in maximum concentration seen when the dose is increased five-fold. No significant effect was observed on the obtained plasma level of VIII:C when the subcutaneous injection volume was changed from 9.4 to 47 ml/kg while the dose of r-VIII SQ was kept constant. Furthermore, the VIII:C obtained in plasma was essentially not dependent on the osmolality of the administration solution.

35

3. The bioavailability of r-VIII SQ after subcutaneous administration in mouse was about 10% of the bioavailability after intrave-

nous administration. The bioavailability was calculated from the area under the activity (VIII:C) - time curve.

EXAMPLE 2.

5

Plasma derived factor VIII was used.

The composition of the frozen solution containing plasma derived factor VIII was the following:

10

Composition per ml:

L-Histidine, mg	7.8
Sodium chloride, mg	35.1
Calcium chloride · (2 H ₂ O), mg	0.59
15 Polyethyleneglycol (PEG 4000), mg	1.0
Albumin human, mg	10.0
VIII:C, IU/ml	250

20 Male albino mice weighing about 30 g and of strain NMRI, SPF, were injected subcutaneously in the neck with the reconstituted factor VIII solution.

The volume injected at the dose level of 10 000 IU/kg was about 40 ml/kg. In the placebo treatment a solution containing 9%
25 (w/v) sodium chloride was used. 3-5 minutes before the blood sampling the mice were anaesthetized intra peritoneally with Mebumal[®] (pentobarbital) vet. 60 mg/ml. The dose volume was about 1.2 ml/mouse. Under anaesthesia 0.45 ml blood was collected from vena cava in plastic syringes containing 0.05 ml sodium
30 citrate (0.13 M). Plasma was prepared from the blood by centrifugation (8800 g for 7 minutes) and thereafter stored in plastic Cryoflex tubes at -70 °C until determination of VIII:C.

Results:

TABLE 3

5 VIII:C in plasma from mice receiving plasma derived factor VIII, 10 000 IU/kg, subcutaneously. VIII:C in the administration solution was about 250 IU/ml.

10	Time after administration (hours)	VIII:C (IU/ml) X±SD	n number of observations
	0	1.04±0.30	4
	1	1.20±0.53	4
15	1.5	1.39±0.04	4
	2	0.85±0.34	4
	4	1.19±0.49	4
	6	1.32±0.53	4
	8	1.15±0.39	4
20	16	1.27±0.08	4
	20	1.17±0.41	4
	24	1.32±0.21	4

Results:

25

1. The bioavailability of plasma derived factor VIII is fairly low according to the results of the in vivo study in mice (Table 3). The bioavailability of plasma derived factor VIII is roughly about 1/10 of the bioavailability of r-VIII SQ. Hence, the bioavailability of r-VIII SQ is substantially higher than the bioavailability of factor VIII derived from human plasma. The maximum plasma level of VIII:C is seen about 1.5 hours after subcutaneous administration.

30

EXAMPLE 3

35

Recombinant factor VIII was prepared according to the method described under Experimental with the following exceptions: (i) the

material of r-VIII SQ that was received from the final purification step was diluted with a buffer not containing PEG, (ii) the r-VIII SQ solution was not freeze-dried, it was stored at -70°C.

5 The r-VIII SQ-solution had the following composition:

	Composition per vial:	
	L-Histidine, mg	7.5
	Sucrose, mg	158
10	Sodium chloride, mg	45
	Calcium chloride · (2 H ₂ O), mg	1.25
	Polyoxyethylene-(20)-sorbitan monooleate (Tween 80®), mg	0.50
	VIII:C charged, IU/vial	6070
	VIII:C, IU/ml *	1130
15	* Diluted r-VIII SQ-solution (1 part of r-VIII SQ-solution + 1 part of water, v:v)	

20 The r-VIII SQ-solution was diluted with sterile water for injection (1 part of r-VIII SQ-solution + 1 part of water, v:v) prior to administration when the dose of VIII:C was below 3000 IU/kg body-weight.

25 Female cynomolgus monkey (*Macaca fascicularis*) weighing about 3-3.5 kg were injected with the r-VIII SQ-solution subcutaneously in the dorsal region. Depending on the dose, the volume of injection was varied between approximately 0.2 to 2.0 ml/kg body-weight. Subcutaneous injections with single doses of 250, 2500 and 5000 IU/kg were administered. On each sampling occasion 1.8
30 ml of blood was collected into tubes containing citrate as anticoagulant (0.2 ml). After centrifugation plasma was separated and frozen in aliquots (< -60°C).

Results:

TABLE 4

- 5 VIII:C in plasma from monkeys receiving r-VIII SQ, 250 IU/kg, subcutaneously. The VIII:C in the administration solution was about 1130 IU/ml.

Monkey No	1	2	3
10			
	VIII:C (IU/ml)	VIII:C (IU/ml)	VIII:C (IU/ml)
	0	1.49	1.76
15	1	1.75	1.92
	4	1.52	1.89
	8	1.67	1.92
	10	1.76	2.03
	12	1.70	2.01
20	14	1.69	2.00
	24	1.32	1.98
	30	1.46	1.90
	48	1.64	1.96

TABLE 5

VIII:C in plasma from monkeys receiving r-VIII SQ, 2500 IU/kg, subcutaneously. The VIII:C in the administration solution was about 1130 IU/ml.

5		4	5	6
Monkey No		VIII:C (IU/ml)	VIII:C (IU/ml)	VIII:C (IU/ml)
10	Sampling after inj. (Hours)			
	0	1.95	1.35	2.30
	2	2.43	1.86	3.05
	6	3.51	2.45	3.59
	9	3.91	2.47	4.16
15	11	3.47	2.24	3.68
	13	3.11	2.06	3.34
	22	2.38	1.55	2.79
	40	2.01	1.49	2.38

20

TABLE 6

VIII:C in plasma from monkeys receiving r-VIII SQ, 5000 IU/kg, subcutaneously. The VIII:C in the administration solution was about 2470 IU/ml.

25		7	8	9
Monkey No		VIII:C (IU/ml)	VIII:C (IU/ml)	VIII:C (IU/ml)
30	Sampling after inj. (Hours)			
	0	2.04	1.78	1.54
	2	2.99	2.37	2.99
	6	4.56	3.33	5.32
	9	4.75	3.89	5.70
	11	4.72	3.82	5.46
35	13	4.23	3.06	4.63
	22	3.03	2.33	3.46
	40	2.76	1.77	2.60

TABLE 7

Dose - Response in monkey receiving r-VIII SQ subcutaneously.

Dose: Dose r-VIII SQ administered (IU/kg bodyweight).

Response: VIII:C in plasma (IU/ml) about 9 hours after administration.

	Dose (IU/kg)	Response (IU/ml)	Response (IU/ml, baseline adj.)	n number of observations
5				
10	Blank (baseline)	1.8 ± 0.3	-	9
	250		0.37 ± 0.05	3
	2500		1.70 ± 0.06	3
15	2500		2.05 ± 0.57	3
	5000		3.4 ± 1.20	3

Results

- 20 1. According to the results (table 4-6) the plasma concentration as a function of time follows the typical pattern for a drug being absorbed after subcutaneous administration. The maximum concentration of VIII:C is seen about 9 hours after administration.
- 25 2. The dose-response relationship obtained (table 7), gives a further verification that there is an absorption of VIII:C into the blood stream following a subcutaneous injection.
- 30 3. The bioavailability of r-VIII SQ after subcutaneous administration in monkey was about 5-10 %. The bioavailability was calculated from the area under the activity (VIII:C) - time curve. The bioavailability was essentially independent of the dose of r-VIII SQ.

CLAIMS

- 5 1. A pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising highly purified recombinant coagulation factor VIII in a concentration of at least 1000 IU/ml, which formulation gives a therapeutic level of factor VIII activity in the blood after administration.
- 10 2. A formulation according to claim 1 which is adopted for subcutaneous administration.
- 15 3. A formulation according to any of claims 1 to 2 in which the factor VIII activity is more than 1500 IU/ml, preferably from 5000 to 100000 IU/ml.
- 20 4. A formulation according to any of claims 1 to 3 which has a volume of 0.1 to 2 ml, preferably 0.5 to 1 ml.
- 25 5. A formulation according to any of claims 1 to 4 in which factor VIII has been chemically modified.
6. A formulation according to any of claims 1 to 5 in which factor VIII is a deletion derivative of recombinant coagulation factor VIII.
- 30 7. A formulation according to claim 1, comprising
 - i) at least 1500 IU/ml of a deletion derivative of recombinant factor VIII
 - 35 ii) at least 0.01 mg/ml of a polyoxyethylene sorbitan fatty acid ester
 - iii) sodium chloride, preferably in an amount of more than 0.1 M.
 - iv) calcium salt, such as calcium chloride or calcium gluconate, preferably in an amount of more than 0.5 mM.
 - v) an amino acid, such as L-histidine, in an amount of more than 1 mM.

8. A formulation according to claims 6 or 7 in which the deletion derivative factor VIII is deletion derivative recombinant factor VIII SQ (r-VIII SQ).
- 5 9. A formulation according to any of claims 1 to 8 which is a stable aqueous solution ready for administration.
- 10 10. A formulation according to any of claims 1 to 8 which is freeze-dried and reconstituted with sterile water or a pharmaceutically acceptable buffer solution before administration.
- 15 11. A formulation according to any of claims 1 to 8 which is mixed or reconstituted with an aqueous solution containing absorption enhancers or protease inhibitors before administration.
- 20 12. Use of a formulation according to any of claims 1-11 for the manufacture of a medicament for subcutaneous, intramuscular or intradermal administration for treating haemophilia.
- 25 13. Use of a deletion derivative of recombinant factor VIII for the manufacture of a medicament for subcutaneous administration.
- 30 14. Use of a formulation or deletion derivative according to claims 12 or 13, where the medicament is in a stable aqueous solution or dispersion, or is freeze-dried.
15. Method for treatment of haemophilia by subcutaneous, intramuscular or intradermal administration of a formulation according to any of claims 1-11.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00297

A. CLASSIFICATION OF SUBJECT MATTER		
IPC5: A61K 37/547, A61K 37/02, A61K 35/16 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC5: A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
MEDLINE, BIOSIS, EMBASE, WPI, WPIL, CLAIMS, US PATENTS FULLTEXT DATAS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO, A1, 9324137 (BRITISH TECHNOLOGY GROUP LTD), 9 December 1993 (09.12.93), the claims; page 3, lines 15-23 --	1-14
X	MEDICAL INTELLIGENCE-POOL ET AL., Volume 275, No 10, Sept 1966, JUDITH GRAHAM POOL, PH.D. et al, "Ineffectiveness of Intramuscularly Injected Factor VIII Concentrate in Two Hemophilic Patients" page 547 - page 548 --	1-14
A	ARZNEIM.-FORSCH./DRUG RES., Volume 38, No 9, 1988, G. B. Gervasi et al, "Decrease of Bleeding Time by a Peptide Fraction from Bovine Factor VIII in Laboratory Animals" page 1268 - page 1270 --	1-14
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
6 October 1994		12 -10- 1994
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Carolina Palmcrantz Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 94/00297

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP, A1, 0104356 (THE UNIVERSITY OF ROCHESTER), 4 April 1984 (04.04.84), claim 7 -- -----	1-14

INTERNATIONAL SEARCH REPORT

International application No.

SE 94/00297

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 15
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.IV: Methods for the treatment of the human or animal body by surgery or therapy as well as diagnostic methods.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

27/08/94

International application No.

PCT/SE 94/00297

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9324137	09/12/93	NONE	
EP-A1- 0104356	04/04/84	SE-T3- 0104356	
		AU-B- 567683	03/12/87
		AU-A- 1747283	09/02/84
		CA-A- 1213214	28/10/86
		JP-A- 59044322	12/03/84
		US-A- 4495175	22/01/85
		US-A- 4614795	30/09/86